0001415889-24-011705.txt : 20240429
0001415889-24-011705.hdr.sgml : 20240429
20240429181103
ACCESSION NUMBER: 0001415889-24-011705
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240425
FILED AS OF DATE: 20240429
DATE AS OF CHANGE: 20240429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Posard Matthew L.
CENTRAL INDEX KEY: 0001543792
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32335
FILM NUMBER: 24893260
MAIL ADDRESS:
STREET 1: 11099 N. TORREY PINES ROAD
STREET 2: SUITE 100
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001159036
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880488686
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 794-8889
MAIL ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC
DATE OF NAME CHANGE: 20040312
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC
DATE OF NAME CHANGE: 20010912
4
1
form4-04292024_100445.xml
X0508
4
2024-04-25
0001159036
HALOZYME THERAPEUTICS, INC.
HALO
0001543792
Posard Matthew L.
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO
CA
92130
true
false
false
false
0
Common Stock
2024-04-25
4
A
0
6501
0
A
119755
D
Option to Purchase Common Stock
38.46
2024-04-25
4
A
0
8804
0
A
2034-04-25
Common Stock
8804
8804
D
Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.
/s/ James Oehler, Attorney-in-Fact
2024-04-29